Last updated: 2026-10-01 07:59:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
TransCode Therapeutics, Inc. (RNAZ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.65, with a market capitalization of $27.60M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $20.99. This page covers its latest market performance, valuation, price trends and company information.
$27.60M | |
$1.66 | |
$5,174,400.00 | |
$1.58 | |
$1.63 | |
6.55K | |
52.87K | |
-- | |
$20.99 | |
$1.58 | |
-- | |
-- |
TransCode Therapeutics, Inc. (RNAZ) last closed at $1.63 as of 2026-09-30 23:31:00, unchanged from the previous close of $1.63.
During the latest regular trading session, RNAZ traded between $1.58 and $5,174,400.00, with a volume of 6.55K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, TransCode Therapeutics, Inc. (RNAZ) moved from $1.77 to $1.65, representing a decline of 6.78% ($0.12).
The stock traded between $1.60 and $2.39 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 83.87 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
RNAZ is currently trading at $1.65, placing it 0.4% of the way from its 52-week low of $1.58 to its 52-week high of $20.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TransCode Therapeutics, Inc. (RNAZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.